Literature DB >> 7945773

The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells.

R Testi1, D D'Ambrosio, R De Maria, A Santoni.   

Abstract

CD69 was initially described as being restricted to recently activated lymphoid cells, but is now known to be expressed on the surface of all hematopoietically derived leukocytes. Crosslinking of CD69 generates intracellular signals in all cell lineages studied, both mouse and human, and results in a variety of cellular end responses. Since a specific ligand has not yet been identified, a definite functional identity for CD69 is still missing. However, as discussed here by Roberto Testi and colleagues, the broad expression of CD69 and its conserved ability to generate intracellular signals suggests a general role for the CD69 receptor in the biology of hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945773     DOI: 10.1016/0167-5699(94)90193-7

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  115 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model.

Authors:  J D Stone; J R Cochran; L J Stern
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

3.  T-cell activation occurs simultaneously in local and peripheral lymphoid tissue following oral administration of a range of doses of immunogenic or tolerogenic antigen although tolerized T cells display a defect in cell division.

Authors:  Karen M Smith; Joanne M Davidson; Paul Garside
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

4.  Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.

Authors:  Qing Ge; Jennifer D Stone; M Todd Thompson; Jennifer R Cochran; Mia Rushe; Herman N Eisen; Jianzhu Chen; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

5.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.

Authors:  C C Murphy; L Duncan; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

7.  The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Authors:  Hong-Sheng Dai; Nathaniel Griffin; Chelsea Bolyard; Hsiaoyin Charlene Mao; Jianying Zhang; Timothy P Cripe; Tadahiro Suenaga; Hisashi Arase; Ichiro Nakano; E A Chiocca; Balveen Kaur; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

8.  Effect of caffeine ingestion on lymphocyte counts and subset activation in vivo following strenuous cycling.

Authors:  Nicolette C Bishop; Christina Fitzgerald; Penny J Porter; Gabriella A Scanlon; Alice C Smith
Journal:  Eur J Appl Physiol       Date:  2004-12-01       Impact factor: 3.078

9.  Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques.

Authors:  David Safronetz; Joseph Prescott; Friederike Feldmann; Elaine Haddock; Rebecca Rosenke; Atsushi Okumura; Douglas Brining; Eric Dahlstrom; Stephen F Porcella; Hideki Ebihara; Dana P Scott; Brian Hjelle; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

10.  CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.

Authors:  David Sancho; Manuel Gómez; Fernando Viedma; Enric Esplugues; Mónica Gordón-Alonso; María Angeles García-López; Hortensia de la Fuente; Carlos Martínez-A; Pilar Lauzurica; Francisco Sánchez-Madrid
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.